{"name":"Jason J. Luke, MD","slug":"jason-j-luke-md","ticker":"","exchange":"","domain":"","description":"Jason J. Luke, MD is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer patients. The company's lead program is a combination of ivosidenib and nivolumab, currently in Phase 2 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOLUpLaHBOXzhrSlAzWmNTUnh5UFAxZjFZQzY5alBVUm4zMlNxa1dJa0NQdWVmanVtal9WZUItc0FuaTFJWEZXdzJHb2doNWtOeVI0Z2wzVWQ1aVBpRE9YakpRNTZYX0Y3VXpTU252eFlCWmwzN1JBazFZdXZjYkhxNkFCNDE3em1uYlVQeHZEalhLV201SUdYOUJKRDhsbVNyUnMxeGRzOUQ0Y19Ea0ZVTmt3Y2hEUDJGTl9jZmJYVy1QdEtlakI0?oc=5","date":"2025-08-21","type":"pipeline","source":"Business Wire","summary":"Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer - Business Wire","headline":"Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPVG5SRGM4bGlKWGc0Yy1SYjFYbDZGTkRxdGhaTGJqdHUtUElQTWh3blpQRzZWRDY1MERScks1dWtSUzVSSlVTbTROekFPeldBSUJVM1Q5Qmxya2lJN3hzSWpfZV9MZ3lJREdkTk1OMU01THh2X2pWN3lyUGllSnMteWxmc1o0WElLOUszYzJwM1FiRFVYbUhNTlNhTUpRV0F3NHY0ZkcxMFZfejVvZGYwcXlYU1hLMkNYTFk5X0tMYWx1WXNXRkFYTFRDSVZxQzJ6M1ZpMjVTZW56NWg4U2lnWW5vN2Q?oc=5","date":"2025-05-29","type":"trial","source":"Business Wire","summary":"Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting - Business Wire","headline":"Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5MNFhIY0I3aVBsT0U5MUpydG85SUI2MnFKc0FpRXV2SjQ1VktoY09Ec2NUMERUMW1aTjA1M3BBUmNBRnNST1J4eXRvbHZDb3ZnOFNEY3JTWXRjZGpkelVj?oc=5","date":"2025-04-09","type":"trial","source":"Nature","summary":"Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial | Nature Medicine - Nature","headline":"Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial | Nature Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQSU1BZmM4NDh0MS1XTWpHOGpCRVotQkV4QXVEUld1bFJOZmgwdnFHZzNXdHJPbS1salBORmN2cDc0YUo1SWZMNlo3RUdXS19RdElXdE9Ga2ZJYkU4MEFCRzdpa3dfZnpfeHhJU1FyMGVLUHJMaHhMX255c080YTlxOE02TlMwd0QtVG91d0U1SVNmWDdHXzJLdjg3dkxlbVZjVlFfZHZSVkJUMHpOZURjam92T1o0TDY5?oc=5","date":"2025-03-17","type":"pipeline","source":"American Association for Cancer Research (AACR)","summary":"Meet The CheckPoints: A Band of Researchers and Oncologists Giving Cancer Treble - American Association for Cancer Research (AACR)","headline":"Meet The CheckPoints: A Band of Researchers and Oncologists Giving Cancer Treble - American Association for Cancer Resea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE5NMXNORXNadEpmLWxRRkwzSHVTcklnNjJBZ0M2RjQ3NVhYMVU5T1VHaWs1OXAwMS1GY2NINzBIV0ZlbTZDaFdZb21XTk1RTEhPS19TTENkTm0xQQ?oc=5","date":"2024-12-23","type":"pipeline","source":"Oncodaily","summary":"Dr. Jason Luke’s Journey in Immuno-Oncology Innovation - Oncodaily","headline":"Dr. Jason Luke’s Journey in Immuno-Oncology Innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQVUNOeWxqanBTd3dOb0QxdndFMVFocHRIRUpoUFFJVEhoVDJ4M3Vub25kbHVOZXBSTWpwY2FWVFVMWVhPNk85X0YxZ3MyLS1aMUFjZC12R2VaQjJkNm5YNERkRkFEVF9qaXZlek05T0RtaGVBTEJYZWhLLUk0R0FZSzk2bkdOU3RiZVRsaGtHaFJuNTdUbDB5RzZvMHVWdl80ZWxDQw?oc=5","date":"2024-12-20","type":"pipeline","source":"CancerNetwork","summary":"Assessing Cosibelimab’s Future in Cutaneous Squamous Cell Carcinoma - CancerNetwork","headline":"Assessing Cosibelimab’s Future in Cutaneous Squamous Cell Carcinoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOMy1MVS02MldwTzNNYTluYVNXTzVOU1owaHFTVm9qS19uVnc5bm13R1RjXzdnLUNzWHVyREdmTTZXdUVzel8wNjlEd0JNbzVVcFVsSFhOcGdka2c3Z1FfWnFMWGdMV3ZvWTlhWERRbk5FVS1WYjhYZDdIQ1JjRV9QdXVmTXItZ1lVMlZDbHZYT25nSy14bkh3d0pnaFY2VEd4OG1pdEdMcFBfczA?oc=5","date":"2024-05-30","type":"regulatory","source":"Targeted Oncology","summary":"FDA Greenlights First-in-Human Trial of ACTM-838 for Advanced Solid Tumors - Targeted Oncology","headline":"FDA Greenlights First-in-Human Trial of ACTM-838 for Advanced Solid Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQZ3U5Uks2ZXpJSm9YSE53eEIxd2pWYUtmWnM5LTU3Z2dQS2xvU1NyZlhCQjVKVTAxQXZGdXF3MjRsZDJaQUVJRE5KeEJILUVhREFpNDNvR2pvZl9aS3h5Z1dOQVZsbjNLQk5JdkxMZFNiNXc0di1CWTVJX0NFU00tZHlrUjYyTHM3azF3ZHBlU01NdE1EenFmQ2xnSlpydEZqa0dzUF9fN19RV3Z3ZWFj?oc=5","date":"2023-10-16","type":"regulatory","source":"CancerNetwork","summary":"FDA Approves Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma - CancerNetwork","headline":"FDA Approves Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPc2RndldmR184Si1PQXB1RjV0dGwwYUtZM1RzampGN1VZMHdNbTVzYS1zb0xQWkJuWnE2U1pzNnNBNWxUNEgzcmNzVWZFSlBXQW9fVE9lVVEwVTZpXzNKczNhXzNxS2N2dzAybm9TSzFNR3Viell1QlYwbUlpelVJOXEwWEZhNDlTdjlTTktZYVlRc2t0c3Q4LUtGOFczZG5KcFdyeTdaOHlKOFhWcWVmWXR2dXh1TVhrY1R3WktXTU90Mk5PcURXcDJXVHRtUQ?oc=5","date":"2021-07-12","type":"pipeline","source":"Healio","summary":"Immunotherapy combination shows antitumor activity in PD-1-refractory melanoma - Healio","headline":"Immunotherapy combination shows antitumor activity in PD-1-refractory melanoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPWi1aTzJCRkNkQTY5SUpZa2R1V0FsMk5kY2NlUEg5TkVoTTJyYjNiV1VrM0ZqMHA2d1V6SmNRY3RBeG94U0oyVU5SUUhMZGJaZWJRamNNOW1VNkNZZDJ6c3RBaExWQ1pCdzNqXzNrQzUzdS1DWmFyWWo0THFKUWRqaVhKMENwUWREQUcyVWt3RTZHZGRHNEViVGpsbXFleWw4cko3eWlhQ1doMFR4VDFjUTZ2Q2FVTXloYmt0eE9yLUxhOW1HMlA3bzdR?oc=5","date":"2021-07-10","type":"pipeline","source":"The ASCO Post","summary":"Responses to Pembrolizumab and Ipilimumab After Anti–PD-1/L1 Failure in Advanced Melanoma - The ASCO Post","headline":"Responses to Pembrolizumab and Ipilimumab After Anti–PD-1/L1 Failure in Advanced Melanoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOOXd2VmZYd3pqR2I5TGYxcmlJek9tV2tab1BnMDV3aUdiRFlSUjJjR014b2tlTFgxZC1rd2xwQ1RVWk0zTWV3a0Vma0VIVkNOa21TaC1ZaHgzVXNlRjVTUTZDU0RfaWNlX1FjOWl6c3dkcXdoX1RTMVMyOFhaRnY4UkUxelVSbFRIYm5MbEs2LXk0SEQ4RlU2NEZqdTNhdXZzWUtUUnZqOVY3R0lSQ245Qno2VTd1QTIxcEI0dVNOaTZyS0dHRjJ4dHdVVzhrTjdwMTNGbkprb1VERjNlU1l1SA?oc=5","date":"2021-06-23","type":"pipeline","source":"Healio","summary":"Durability of lifileucel linked to duration of immune checkpoint inhibitor use in melanoma - Healio","headline":"Durability of lifileucel linked to duration of immune checkpoint inhibitor use in melanoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE04bHBsU3dET05PUHZwWkVUbzEzZHdUMXAxNExzakVWSXIteEFBdC1paHFsY2xEZzAyRWZlVWtja0xLMFl3UWp5QXQ2UVAzLUk0RHVhMWkxdEd0UDdBVVNiZlBOUXNqMGpzaEVMb000U1VaNlZEZmRhWXpWbw?oc=5","date":"2019-01-28","type":"trial","source":"Wiley","summary":"A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma - Wiley","headline":"A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanc","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}